Diabetes
Refine search
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca is moving its oral GLP-1 receptor agonist elecoglipron into an extensive Phase III program after positive Phase IIb results in obesity and type 2 diabetes. 9 June 2026
Pharmaceutical
Boston, USA-based cardiometabolic specialist Sparrow Pharmaceuticals announced positive Phase II clinical data for clofutriben, its lead investigational 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, in adults with type 2 diabetes (T2D) at the 2026 Annual American Diabetes Association (ADA) Scientific Session. 9 June 2026
Pharmaceutical
US biopharma company MannKind Corporation has presented new clinical and real-world data on Afrezza (insulin human) at the American Diabetes Association’s 2026 Scientific Sessions, adding to evidence supporting the inhaled insulin’s use across a broader range of diabetes patients. 8 June 2026
Pharmaceutical
Danish pharma Novo Nordisk has reported positive Phase III diabetes data for CagriSema, giving the once-weekly GLP-1/amylin combination another platform as it awaits a US regulatory decision in obesity. 8 June 2026
Pharmaceutical
Danish pharma Novo Nordisk has presented a batch of post hoc semaglutide analyses at the American Diabetes Association meeting, using data from SELECT, STEP, ESSENCE and OASIS trials to press the drug’s case across obesity-related complications. 8 June 2026
Pharmaceutical
Danish pharma major Novo Nordisk announced new clinical data from the positive Phase II trial of investigational zenagamtide, also known as amycretin. Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors. 8 June 2026
Pharmaceutical
Bayer has announced that the US Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for Kerendia (finerenone), which is being investigated for the treatment of adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). 21 May 2026
Biosimilars
Swiss drugmaker Sandoz today confirmed that the European Commission has granted marketing authorization for Bysumlog (insulin lispro) and Dazparda (insulin aspart). The two biosimilar insulins, for injection in prefilled pens, are developed by Gan & Lee Pharmaceuticals. 15 May 2026
Pharmaceutical
Germany’s Merck KGaA has reported first-quarter 2026 results ahead of analyst expectations and raised its full-year guidance, driven by strong momentum in its Life Science business and resilience in Healthcare. 13 May 2026
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS) will provide eligible Medicare beneficiaries access to certain GLP-1 medications for $50 per month beginning July 1, 2026, through December 31, 2027. 7 May 2026
Biosimilars
US generic drugmaker Lannett said the US regulator has approved Langlara (insulin glargine-aldy), an interchangeable biosimilar to Sanofi’s long-established diabetes treatment Lantus (insulin glargine). 6 May 2026
Pharmaceutical
Danish pharma major Novo Nordisk today released financial results, showing that first-quarter 2026 sales jumped 32% on a constant exchange rate (CER) basis to 96.8 billion kroner ($15.2 billion), well above an analyst consensus of 71.3 billion kroner compiled by FactSet. 6 May 2026
Pharmaceutical
London-based financial services company Deloitte has released its 16th annual pharma innovation report which looks at the current state of R&D for 20 leading pharma companies. 5 May 2026
Generics
India’s OneSource Specialty Pharma, a specialty pharmaceutical contract manufacturer, has announced that its partner Orbicular, along with its Canadian front-end partner, has received approval from Health Canada for a generic version of Ozempic (semaglutide injection). 5 May 2026
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday announced it is proposing to exclude semaglutide, tirzepatide and liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. 1 May 2026
Pharmaceutical
US pharma major Eli Lilly delivered a standout first quarter of 2026, with financial results comfortably exceeding market expectations. 30 April 2026
Pharmaceutical
US pharma major Eli Lilly commends the actions taken by the Haryana drug control authority in addressing counterfeit products falsely bearing the Mounjaro (tirzepatide) brand name that were recently seized in Gurugram, Haryana. 30 April 2026
Pharmaceutical
Danish drugmaker Novo Nordisk has reported positive Phase IIIa results for oral semaglutide, showing improved blood sugar control in children and adolescents with type 2 diabetes, a group with limited treatment options. 27 April 2026
Pharmaceutical
Novo Nordisk today announced positive top-line results from PIONEER TEENS, a phase 3a trial evaluating oral semaglutide for type 2 diabetes in children and adolescents aged 10–17 years with type 2 diabetes. 23 April 2026
Biotechnology
The US Food and Drug Administration (FDA) has approved Sanofi’s supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years and older to as young as one year of age to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. 22 April 2026
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca is moving its oral GLP-1 receptor agonist elecoglipron into an extensive Phase III program after positive Phase IIb results in obesity and type 2 diabetes. 9 June 2026
Pharmaceutical
Boston, USA-based cardiometabolic specialist Sparrow Pharmaceuticals announced positive Phase II clinical data for clofutriben, its lead investigational 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, in adults with type 2 diabetes (T2D) at the 2026 Annual American Diabetes Association (ADA) Scientific Session. 9 June 2026
Pharmaceutical
US biopharma company MannKind Corporation has presented new clinical and real-world data on Afrezza (insulin human) at the American Diabetes Association’s 2026 Scientific Sessions, adding to evidence supporting the inhaled insulin’s use across a broader range of diabetes patients. 8 June 2026
Pharmaceutical
Danish pharma Novo Nordisk has reported positive Phase III diabetes data for CagriSema, giving the once-weekly GLP-1/amylin combination another platform as it awaits a US regulatory decision in obesity. 8 June 2026
Pharmaceutical
Danish pharma Novo Nordisk has presented a batch of post hoc semaglutide analyses at the American Diabetes Association meeting, using data from SELECT, STEP, ESSENCE and OASIS trials to press the drug’s case across obesity-related complications. 8 June 2026
Pharmaceutical
Danish pharma major Novo Nordisk announced new clinical data from the positive Phase II trial of investigational zenagamtide, also known as amycretin. Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors. 8 June 2026
Pharmaceutical
Bayer has announced that the US Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for Kerendia (finerenone), which is being investigated for the treatment of adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). 21 May 2026
Biosimilars
Swiss drugmaker Sandoz today confirmed that the European Commission has granted marketing authorization for Bysumlog (insulin lispro) and Dazparda (insulin aspart). The two biosimilar insulins, for injection in prefilled pens, are developed by Gan & Lee Pharmaceuticals. 15 May 2026
Pharmaceutical
Germany’s Merck KGaA has reported first-quarter 2026 results ahead of analyst expectations and raised its full-year guidance, driven by strong momentum in its Life Science business and resilience in Healthcare. 13 May 2026
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS) will provide eligible Medicare beneficiaries access to certain GLP-1 medications for $50 per month beginning July 1, 2026, through December 31, 2027. 7 May 2026
Biosimilars
US generic drugmaker Lannett said the US regulator has approved Langlara (insulin glargine-aldy), an interchangeable biosimilar to Sanofi’s long-established diabetes treatment Lantus (insulin glargine). 6 May 2026
Pharmaceutical
Danish pharma major Novo Nordisk today released financial results, showing that first-quarter 2026 sales jumped 32% on a constant exchange rate (CER) basis to 96.8 billion kroner ($15.2 billion), well above an analyst consensus of 71.3 billion kroner compiled by FactSet. 6 May 2026
Pharmaceutical
London-based financial services company Deloitte has released its 16th annual pharma innovation report which looks at the current state of R&D for 20 leading pharma companies. 5 May 2026
Generics
India’s OneSource Specialty Pharma, a specialty pharmaceutical contract manufacturer, has announced that its partner Orbicular, along with its Canadian front-end partner, has received approval from Health Canada for a generic version of Ozempic (semaglutide injection). 5 May 2026
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday announced it is proposing to exclude semaglutide, tirzepatide and liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. 1 May 2026
Pharmaceutical
US pharma major Eli Lilly delivered a standout first quarter of 2026, with financial results comfortably exceeding market expectations. 30 April 2026
Pharmaceutical
US pharma major Eli Lilly commends the actions taken by the Haryana drug control authority in addressing counterfeit products falsely bearing the Mounjaro (tirzepatide) brand name that were recently seized in Gurugram, Haryana. 30 April 2026
Pharmaceutical
Danish drugmaker Novo Nordisk has reported positive Phase IIIa results for oral semaglutide, showing improved blood sugar control in children and adolescents with type 2 diabetes, a group with limited treatment options. 27 April 2026
Pharmaceutical
Novo Nordisk today announced positive top-line results from PIONEER TEENS, a phase 3a trial evaluating oral semaglutide for type 2 diabetes in children and adolescents aged 10–17 years with type 2 diabetes. 23 April 2026
Biotechnology
The US Food and Drug Administration (FDA) has approved Sanofi’s supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years and older to as young as one year of age to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. 22 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze